Simos Simeonidis
Recent Quotes
"Given CYTR's valuation, we view the current risk/reward as favorable."
—
Simos Simeonidis, Cowen & Co.
(5/10/13)
more >
"We rate CYTR Outperform."
—
Simos Simeonidis, Cowen & Co.
(3/11/13)
more >
"Aldoxorubicin continues to be the most promising compound in CYTR's pipeline."
—
Simos Simeonidis, Cowen & Co.
(11/9/12)
more >
"We are initiating coverage of IMUC."
—
Simos Simeonidis, Cowen & Co.
(2/17/12)
more >
Due to permission requirements, not all quotes are shown.
